Factors predictive of the development of levodopa-induced dyskinesia and Wearing-Off in Parkinson's disease

Movement Disorders

Volumn 29, Issue 3, 2014, Pages 429-429

  Rajput, Ali H ^a  

^a SASKATOON HEALTH REGION   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; LEVODOPA; ANTIPARKINSON AGENT;

AUTOPSY; DYSKINESIA; HUMAN; INCIDENCE; LETTER; NEUROLOGIST; PARKINSON DISEASE; PREDICTION; PRIORITY JOURNAL; DYSKINESIA, DRUG-INDUCED; FEMALE; MALE;

ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE;

EID: 84896128233     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25800     Document Type: Letter

References (6)

1. Olanow WC, Kieburtz K, Rascol O, et al; Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) Investigators. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 2013;28:1064-1071.
2. Birkmayer W, Hornykiewicz O. The effect of L-3, 4-dihydroxyphenylalanine (L-DOPA) on akinesia in Parkinsonism. Wiener Klin Wochenschr 1961;73:787-788.
3. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379.
4. Yahr MD. Clinical aspects of abnormal movements induced by L-dopa. In: Barbeau A, McDowell FH, editors. L-Dopa and Parkinsonism. Philadelphia, PA: F.A. Davis Company; 1970:101-108.
5. Rajput AH, Stern W, Laverty WH. Chronic low dose therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology 1984;34:991-996.
6. Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A. Course in Parkinson's disease subtypes: a 39-year clinicopathological study. Neurology 2009;73:206-212.